CD8A and infection: Notably, low-dose ACT with just 100 OT-I cells significantly reduced the infection in all three organs tested, which is in good agreement with clinical data on low-dose ACT with streptamer-enriched hCMV-specific CD8+ T cells into HCT recipients, as reported by Stemberger and colleagues (33).